Fasudil (WP-0512) ( DrugBank: Fasudil )


1 disease
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis1

2. Amyotrophic lateral sclerosis


Clinical trials : 624 Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05218668
(ClinicalTrials.gov)
December 22, 202123/11/2021Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisDrug: Fasudil (WP-0512)Woolsey PharmaceuticalsNULLRecruiting18 Years75 YearsAll20Phase 2United States;Australia